Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
N/A
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05954286Phase 2Completed

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

Role: collaborator

NCT06925919Phase 1Active Not Recruiting

Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011

Role: collaborator

NCT06507566Not ApplicableCompleted

Evaluating Technologies for Point-of-Care Blood Collections by Patients

Role: collaborator

NCT04844541Completed

Prophylaxis and Treatment of COVID-19

Role: collaborator

All 4 trials loaded